
CITATION REPORT List of articles citing



DOI: 10.1038/s41584-020-0419-z Nature Reviews Rheumatology, 2020, 16, 335-345.

Source: https://exaly.com/paper-pdf/77573379/citation-report.pdf

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
262	Outlook of IL-6 signaling blockade for COVID-19 pneumonia. 2020 , 40, 24		13
261	The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019. 2020 , 2, e0203		16
260	Calcinosis: insights from other calcinoses. 2020 , 32, 472-478		2
259	Epigenetic Regulations of AhR in the Aspect of Immunomodulation. 2020 , 21,		2
258	Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients. 2020 , 11, 572475		5
257	Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. 2021 , 268, 4522	-4536	16
256	Cytokine Storms in Cancer and COVID-19. 2020 , 38, 598-601		32
255	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. 2020 , 117, 27141-27147		91
254	Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?. 2020 , 7, 571597		5
253	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. 2020 , 18, 3774-3787		11
252	An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. 2020 , 17, 34		7
251	Role of adiposopathy and physical activity in cardio-metabolic disorder diseases. 2020 , 511, 243-247		2
250	Biotherapies in Uveitis. 2020 , 9,		10
249	Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. 2020, 21,		46
248	Cytokine Profile in an Adolescent With Pediatric Multisystem Inflammatory Syndrome Temporally Related to COVID-19. 2020 , 39, e213-e215		9
247	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. 2020 , 8,		12
246	Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. 2020 , 35, 81-87		16

(2021-2020)

245	Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients. 2020 , 17, 1180-1182	7
244	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. 2020 , 131, 110698	46
243	Co-cultured bone marrow mesenchymal stem cells repair thioacetamide-induced hepatocyte damage. 2020 , 44, 2459-2472	2
242	Investigation of Genetic Variations of and as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory Disorders. 2020 , 10,	9
241	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. 2020 , 61, 381-395	29
240	Se Deficiency Induced Inflammation Resulting to a Diminished Contraction of the Small Intestinal Smooth Muscle in Mice. 2021 , 199, 1437-1444	3
239	Repurposed Tocilizumab in Patients with Severe COVID-19. 2021 , 206, 599-606	11
238	Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis. 2021 , 73, 1053-1061	8
237	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. 2020 , 11, 607583	4
236	Inflammatory stress in SARS-COV-2 associated Acute Kidney Injury. 2021 , 17, 1497-1506	5
235	Inference of an integrative, executable network for Rheumatoid Arthritis combining data-driven machine learning approaches and a state-of-the-art mechanistic disease map.	O
234	COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario. 2021 , 28, 100425	O
233	The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course. 2021 , 15, 36-51	1
232	Sleep disorders are associated with acetaminophen-induced adverse reactions and liver injury. 2021 , 134, 111150	3
231	Onset of pyoderma gangrenosum after tocilizumab therapy for Takayasu arteritis: A new undescribed paradoxical reaction. 2021 , 87, 3378-3379	1
230	IL-6R blockade by chikusetsusaponin IVa butyl ester inhibits Th17´cell differentiation and ameliorates collagen-induced arthritis. 2021 , 18, 1584-1586	
229	The effect of olokizumab on rheumatoid arthritis patient reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1). 2021 , 59, 62-69	2
228	Quicker and digital: the way on protein biomarkers?. 2021 , 137, 1564-1565	

227	Coronavirus disease 2019 (COVID-19) and autoimmunity. 2021 , 59, 5-30	18
226	Cytokines that Modulate the Differentiation of Th17 Cells in Autoimmune Uveitis. 2021 , 2021, 6693542	2
225	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. 2021 , 31, 2100088	21
224	Correlation between serum cysteine-rich protein 61 and disease activity of antineutrophil cytoplasmic antibody-associated vasculitis. 2021 , 40, 3703-3710	O
223	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. 2021 , 10,	6
222	Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus. 2021 , 17, e1009505	2
221	Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation.	1
220	The Immunomodulatory and Anti-Inflammatory Effect of Curcumin on Immune Cell Populations, Cytokines, and In Vivo Models of Rheumatoid Arthritis. 2021 , 14,	11
219	Capturing Cytokines with Advanced Materials: A Potential Strategy to Tackle COVID-19 Cytokine Storm. 2021 , 33, e2100012	16
218	JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?. 2021 , 23, 34	5
217	Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases. 2021 , 26, 1030-1039	6
216	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. 2021 , 37, 929-938	4
215	Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC).	1
214	The role of IL-6 and IL-6 blockade in COVID-19. 2021 , 17, 601-618	10
213	Old and New Challenges in Uveitis Associated with Behāt's Disease. 2021 , 10,	1
212	IL-6 signaling mediates the germinal center response, IgM production and nociceptive sensitization in male mice after tibia fracture. 2021 , 94, 148-158	3
211	Case Report: A Case of Intestinal Behët's Disease Exhibiting Enhanced Expression of IL-6 and Forkhead Box P3 mRNA After Treatment With Infliximab. 2021 , 8, 679237	1
210	Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells.	

209	Two Cases of Extremely High-IL-6 Pan-uveitis with Subretinal Exudation and Cell Migration. 2021, 1-5	1
208	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. 2021 , 9,	3
207	Association of Serum IL-6 (Interleukin 6) With Functional Outcome After Intracerebral Hemorrhage. 2021 , 52, 1733-1740	3
206	Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis. 2021 , 10,	2
205	Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease. 2021 , 1-7	1
204	Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions. 2021 , 12, 651971	3
203	Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. 2021 , 9, 655-664	32
202	Brain Mechanisms of COVID-19-Sleep Disorders. 2021 , 22,	5
201	Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date. 2021 , 14, 1279-1287	1
200	Genetic and functional evidence for gp130/IL6ST-induced TRPA1 upregulation in uninjured but not injured neurons in a mouse model of neuropathic pain. 2021 ,	2
199	Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience. 2021 , 26, 1591-1601	2
198	Tocilizumab Induces IL-10-Mediated Immune Tolerance in Invasive Candidiasis. 2021 , 7,	O
197	Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles. 2021 , 8, 715258	6
196	Inference of an Integrative, Executable Network for Rheumatoid Arthritis Combining Data-Driven Machine Learning Approaches and a State-of-the-Art Mechanistic Disease Map. 2021 , 11,	1
195	Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders. 2021 , 229, 108790	1
194	Requirement of Histone Deacetylase 6 for Interleukin-6 Induced Epithelial-Mesenchymal Transition, Proliferation, and Migration of Peritoneal Mesothelial Cells. 2021 , 12, 722638	O
193	Role of IL-6 in the regulation of neuronal development, survival and function. 2021 , 144, 155582	6
192	Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation. 2021 , 11, 16483	3

191	Role of temporal artery resection in Horton's arteritis (Review). 2021 , 22, 1099	О
190	-Regulated Transcriptome and Its Therapeutic Significance in Ovarian Cancer. 2021 , 11,	2
189	Investigation on the mechanisms of guiqi huoxue capsule for treating cervical spondylosis based on network pharmacology and molecular docking. 2021 , 100, e26643	1
188	Patients with mesenchymal tumours and high prevalence have worse prognosis in colorectal cancer (CRC). 2021 ,	2
187	Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. 2021 , 3, e619-e626	4
186	In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR. 2021 , 101, 108201	3
185	Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease. 2021 ,	1
184	Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. 2021 , 19, 144	O
183	Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis. 2021 , 110, 320-329	5
182	Nanocarriers for oral delivery of biologics: small carriers for big payloads. 2021 , 42, 957-972	8
181	Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes. 2021 , 48, 128229	2
180	Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells. 2021 , 118,	O
179	IL-6 enhances CD4 cell motility by sustaining mitochondrial Ca through the noncanonical STAT3 pathway. 2021 , 118,	0
178	Inborn errors of IL-6 family cytokine responses. 2021 , 72, 135-145	2
177	Kinase activity profiling reveals contribution of G-protein signaling modulator 2 deficiency to impaired regulatory T cell migration in rheumatoid arthritis. 2021 , 124, 102726	1
176	Unravelling the broader complexity of IL-6 involvement in health and disease. 2021 , 148, 155684	2
175	Tocilizumab for the Treatment of Ocular Inflammatory Disease. 2021 , 29, 2-5	7
174	Pharmacotherapeutics of SARS-CoV-2 Infections. 2021 , 16, 12-37	3

173	Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms. 2021, 14, 175-189	16
172	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
171	The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. 2021 , 31, 927-932	2
170	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. 2021 , 2, 1	6
169	Increased number of cases of giant cell arteritis and higher rates of ophthalmic involvement during the era of COVID-19. 2020 , 4, rkaa067	7
168	New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment. 2021 , 26, 97-105	4
167	Integrative Genetics Analysis of Juvenile Idiopathic Arthritis Identifies Novel Loci.	1
166	Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trial.	3
165	Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19. 2021 , 7,	7
164	IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. 2020 , 58, 245-261	10
164		10
	(COVID-19): FOCUS ON INTERLEUKIN 6. 2020 , 58, 245-261	
163	(COVID-19): FOCUS ON INTERLEUKIN 6. 2020 , 58, 245-261 Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. 2020 , 30, 629-644	4
163	(COVID-19): FOCUS ON INTERLEUKIN 6. 2020 , 58, 245-261 Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. 2020 , 30, 629-644 IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives. 2021 , 22,	3
163 162 161	(COVID-19): FOCUS ON INTERLEUKIN 6. 2020, 58, 245-261 Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. 2020, 30, 629-644 IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives. 2021, 22, Making sense of IL-6 signalling cues in pathophysiology. 2021, Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With	4 3 2
163 162 161 160	(COVID-19): FOCUS ON INTERLEUKIN 6. 2020, 58, 245-261 Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. 2020, 30, 629-644 IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives. 2021, 22, Making sense of IL-6 signalling cues in pathophysiology. 2021, Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. 2021,	4 3 2 5
163 162 161 160	(COVID-19): FOCUS ON INTERLEUKIN 6. 2020, 58, 245-261 Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. 2020, 30, 629-644 IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives. 2021, 22, Making sense of IL-6 signalling cues in pathophysiology. 2021, Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. 2021, JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. 2021, 148, 911-925	4 3 2 5 5

155	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. 2020 , 1, 16	2
154	Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. 2022 , 149, 155742	3
153	Sympathetic nerve-adipocyte interactions in response to acute stress. 2021 , 100, 151	1
152	Development of type 1 diabetes in a patient treated with anti-interleukin-6 receptor antibody for rheumatoid arthritis. 2021 ,	O
151	Rationality of routine clinical use of olokizumab in COVID-19. 2020 , 68-70	3
150	Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets. 2021 , 13, 3925-3941	4
149	Medical Therapy for Craniopharyngiomas 2021 , 17, 121-132	
148	Sarilumab-induced cutaneous adverse event.	
147	Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. 2021 , 19, 391	2
146	Changes of Host Immunity Mediated by IFN-ICD8 T Cells in Children with Adenovirus Pneumonia in Different Severity of Illness 2021 , 13,	1
145	Nanovibrational stimulation inhibits osteoclastogenesis and enhances osteogenesis in co-cultures. 2021 , 11, 22741	
144	Cytokine storm in tuberculosis and IL-6 involvement. 2021 , 105166	O
143	Overactive STAT3 Drives Accumulation of Disease-Associated CD21 low B Cells.	
142	Harnessing cytokines and chemokines for cancer therapy 2022 ,	15
141	Serum levels of Interleukin 22 and Interleukin 6 decrease after treatment in patients with rheumatoid arthritis. 2020 , 40-50	
140	Pursuit and New Trend in Rheumatoid Arthritis. 2020 , 109, 1669-1684	
139	10) From the Perspective of Rheumatology. 2020 , 109, 2040-2045	
138	Interluekin-6 inhibitors for the treatment of adult-onset Still's disease. 2021 ,	3

137	Juvenile idiopathic arthritis 2022 , 8, 5	7
136	Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6 2022 ,	1
135	Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma 2022 , 17, e0262549	O
134	CARD9 Regulation and its Role in Cardiovascular Diseases 2022 , 18, 970-982	4
133	A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential 2021 , 12, 816646	2
132	Alterations in cortisol and interleukin-6 secretion in patients with COVID-19 suggestive of neuroendocrine-immune adaptations 2022 , 75, 317	O
131	Tocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients 2022,	1
130	Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6R L o inhibit IL-6/ IL-6R P gp130 hexameric signaling complex formation 2022 , 14, 2029675	1
129	Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA 2021 , 9, 465	1
128	Targeted Immunotherapy for Autoimmune Disease 2022 , 22, e9	3
127	A hybrid soluble gp130/spike-nanobody fusion protein simultaneously blocks IL-6 trans-signaling and cellular infection with SARS-CoV2 2021 , JVI0162221	О
126	Immunomodulatory and Antitumoral Activity of Gold Nanoparticles Synthesized by Red Algae Aqueous Extracts 2022 , 20,	O
125	Self-assembled human skin equivalents model macrophage activation of cutaneous fibrogenesis in systemic sclerosis 2022 ,	2
124	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling 2022 , 13, 795315	3
123	Interleukin 6 in diabetes, chronic kidney disease and cardiovascular disease: mechanisms and therapeutic perspectives 2022 ,	2
122	Clinical Application of Enteral Nutrition Combined with Microbial Preparation for Intestinal Preparation in Elderly Patients with Colorectal Cancer 2022 , 28, e935366	
121	The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model.	
120	Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity 2022 , 14,	0

119	Immune mechanisms of resistance to cediranib in ovarian cancer 2022,	1
118	Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis 2022 , 23,	2
117	Chronically Elevated -GlcNAcylation Limits Nitric Oxide Production and Deregulates Specific Pro-Inflammatory Cytokines 2022 , 13, 802336	O
116	Research progress in drug therapy of juvenile idiopathic arthritis 2022, 1	1
115	Evaluating the structural and immune mechanism of Interleukin-6 for the investigation of Goat Milk peptides as potential treatments for COVID-19 2022 , 101924	1
114	Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis 2022 , 298, 120516	O
113	Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study 2021 , 11,	1
112	Toward Overcoming Treatment Failure in Rheumatoid Arthritis 2021 , 12, 755844	1
111	Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review 2021 , 9, e05242	1
110	TBK1 recruitment to STING mediates autoinflammatory arthritis caused by defective DNA clearance 2022 , 219,	1
109	BRAF mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs 2021 , 13, 2129-2148	1
108	Modifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding 2021 , 6, 35593-35599	3
107	Overactive STAT3 drives accumulation of disease-associated CD21low B cells.	
106	COVID-19 and Traumatic Brain Injury (TBI); What We Can Learn From the Viral Pandemic to Better Understand the Biology of TBI, Improve Diagnostics and Develop Evidence-Based Treatments 2021 , 12, 752937	
105	Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes. 2022 , 3, 11-16	
104	Myeloid-Derived Suppressor Cells and Radiotherapy 2022 , OF1-OF13	4
103	Interleukin-6 receptor antagonists in immunopsychiatry: can they lead to increased interleukin-6 in the central nervous system (CNS) and worsening psychiatric symptoms?. 2022 ,	1
102	Data_Sheet_1.PDF. 2020 ,	

101	Value of combination of 25-(OH)-D3, IL-6, and cyclic peptide containing citrulline antibodies in different stages of rheumatoid arthritis 2021 , 13, 13599-13607	
100	Elevated White Blood Cell Count and Lactate Dehydrogenase Levels are Important Markers for Diagnosing Relapse of Adult-onset Still's Disease under Tocilizumab Use: A Case Report 2022 ,	
99	Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm 2022 , 23,	2
98	Inborn Errors of the Immune System Associated With Atopy 2022 , 13, 860821	O
97	Molecular Mechanisms and Current Treatment Options for Cancer Cachexia 2022, 14,	2
96	The role of IL-6 in TBI and PTSD, a potential therapeutic target?. 2022 , 218, 107280	O
95	Interleucina-6. 2021 , 12-21	
94	Piezo1: opening the way to preventing muscle atrophy 2022 , 132,	1
93	The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy 2022 ,	Ο
92	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial 2022 ,	5
91	Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-dependent autoimmunity.	1
90	Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis. 2022 , 347, 590-606	1
89	Immune system changes in those with hypertension when infected with SARS-CoV-2. 2022 , 104562	
88	Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. 2022 , 11, 1959	1
87	Indications and effects of biological agents in the treatment of noninfectious uveitis.	0
86	Impact of Chronic Inflammation in Psoriasis on Bone Metabolism. 13,	Ο
85	Role of initial and follow-up IL-6 (Interleukin-6) titre in COVID-19 pneumonia: A single center experience. 2022 , 19, em390	
84	Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Publish Ahead of Print,	O

83	Aging-associated and CD4 T-celldependent ectopic CXCL13 activation predisposes to anti P D-1 therapy-induced adverse events. 2022 , 119,	O
82	HNRNPC downregulation inhibits IL -6/ STAT3 -mediated HCC metastasis by decreasing HIF1A expression.	O
81	The Role of Adipokines in Pancreatic Cancer. 12,	
80	Therapeutics for the management of cytokine release syndrome in COVID-19. 2022 , 22,	2
79	Impact of Formulation Choices on the Freeze-Drying of an Interleukin-6 Reference Material. 9,	
78	Clinical Effect of Emergency Dermabrasion Combined with Biological Dressing A on Wound Microcirculation and Preventing Sepsis in Deep Degree-II Burns. 2022 , 2022, 1-6	
77	IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation. 13,	
76	Influence of genetic ancestry on breast stromal cells provides biologic basis for increased incidence of metaplastic breast cancer in women of African descent.	
75	Roles of Interleukin-6-mediated immunometabolic reprogramming in COVID-19 and other viral infection-associated diseases. 2022 , 110, 109005	
74	The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. 2022 , 84, 105429	Ο
73	IL6 and CCL18 Mediate Cross-talk between VHL-Deficient Kidney Cells and Macrophages during Development of Renal Cell Carcinoma. 2022 , 82, 2716-2733	1
72	IL-6: The Link Between Inflammation, Immunity and Breast Cancer. 12,	2
71	The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19. 13,	О
70	Osteoarthritis and chronic pain: Interleukin-6 as a common denominator and therapeutic target. 2022 , 15,	1
69	Biomarker Changes and Molecular Signatures Associated with Takayasu Arteritis Following Treatment with Glucocorticoids and Tofacitinib. Volume 15, 4395-4407	О
68	Chronic Pain after Bone Fracture: Current Insights into Molecular Mechanisms and Therapeutic Strategies. 2022 , 12, 1056	O
67	Epigenetic reader SP140 loss of function drives Crohn disease due to uncontrolled macrophage topoisomerases. 2022 , 185, 3232-3247.e18	1
66	Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach. 2022 , 111, 109130	3

65	Cbl-b restrains priming of pathogenic Th17 cells via the inhibition of IL-6 production by macrophages. 2022 , 25, 105151	0
64	Pathway and Genomics of Immunomodulator Natural Products. 2022 , 83-114	Ο
63	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. 9,	O
62	Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. 2022 , 15,	1
61	Cerebral Aneurysm and Interleukin-6: a Key Player in Aneurysm Generation and Rupture or Just One of the Multiple Factors?.	0
60	Targeting cancer cachexia: Molecular mechanisms and clinical study. 2022 , 3,	1
59	A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. 2022 , 8, e002359	1
58	Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. 2022 , 24,	Ο
57	Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases. 13,	0
56	Ultra-Sensitive and Semi-Quantitative Vertical Flow Assay for the Rapid Detection of Interleukin-6 in Inflammatory Diseases. 2022 , 12, 756	O
55	A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA[] (ACT)-Bridge study.	1
54	Interleukin-6 in blood and bronchoalveolar lavage fluid of hospitalized children with community-acquired pneumonia. 10,	O
53	Current Research Describing the Role of CD4+ T Lymphocyte Subsets in the Pathogenesis of Granulomatous Lobular Mastitis. 2022 , 35, 1790-1795	0
52	The interleukin-6 family in tissues is closely related to the clinical outcomes of oral lichen planus.	O
51	IL-6-targeted therapies directed to cytokine or receptor blockade drive distinct alterations in T cell function.	0
50	Immune Modulation in Sepsis, ARDS, and Covid-19 T he Road Traveled and the Road Ahead. 2022 , 1,	O
49	Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.	0
48	IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4+ T cells in rheumatoid arthritis. 2022 , 42,	O

47	Transcriptome profiling of abdominal aortic tissues reveals alterations in mRNAs of Takayasu arteritis. 13,	1
46	The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6). 2022 , 60, 505-518	1
45	Effects on Serum Inflammatory Cytokines of Cholecalciferol Supplementation in Healthy Subjects with Vitamin D Deficiency. 2022 , 14, 4823	О
44	Treat the UntreatableDy a Photothermal Agent: Triggering Heat and Immunological Responses for Rabies Virus Inactivation. 2205461	O
43	Decoding the Key Functional Combined Components Group and Uncovering the Molecular Mechanism of Longdan Xiegan Decoction in Treating Uveitis. Volume 16, 3991-4011	0
42	Self-Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design. 2202393	O
41	Inflammation in COVID-19: A Risk for Superinfections. 2022 , 2, 1609-1624	О
40	Inhibitory effects of Ganoderma lucidum spore oil on rheumatoid arthritis in a collagen-induced arthritis mouse model. 2023 , 157, 114067	O
39	The roles and clinical applications of interleukins in endometrial carcinoma. 12,	O
38	The biological role of IL-1, IL-6 and CRP and their application in the diagnosis of the inflammatory process. 2022 , 58, 66-73	O
37	Senescent Schwann cells induced by aging and chronic denervation impair axonal regeneration after peripheral nerve injury.	0
36	Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases ${\bf R}{\bf A}$ as a role model. 2022 , 42,	О
35	Targeting IL -6 to prevent cardiac allograft rejection. 2022 , 22, 12-17	О
34	An interleukin 6-based genetic risk score strengthened with interleukin 10 polymorphisms associated with long-term kidney allograft outcomes. 2022 , 22, 45-57	O
33	Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience. 2022 , 16, 73-79	0
32	IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling.	O
31	Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis. 2023 , 25,	0
30	Refractory Takayasu arteritis with recurrent pyoderma gangrenosum: a therapeutic challenge with case-based review.	O

29	Single-cell computational machine learning approaches to immune-mediated inflammatory disease: New tools uncover novel fibroblast and macrophage interactions driving pathogenesis. 13,	O
28	Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.	O
27	Comparing the Therapeutic Mechanism and Immune Response of Human and Mouse Mesenchymal Stem Cells in Immunocompetent Mice With Acute Liver Failure.	О
26	Double-Stranded RNA Induces Mortality in an MDA5-Mediated Type I Interferonopathy Model. 2022 , 209, 2093-2103	O
25	Sjgren8 syndrome: shedding light on emerging and key drug targets. 1-14	О
24	Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis. 2023 , 13, 82	O
23	Blocage de l'IL-6 hors autorisation de mise sur le march[] 2022 , 215-224	O
22	Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool. 2206517	O
21	IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling.	O
20	MicroRNA Let-7 Induces M2 Macrophage Polarization in COPD Emphysema Through the IL-6/STAT3 Pathway. Volume 18, 575-591	O
19	The Exciting Future for Scleroderma. 2023 , 49, 445-462	О
18	PRRSV-induced inflammation in pulmonary intravascular macrophages (PIMs) and pulmonary alveolar macrophages (PAMs) contributes to endothelial barrier function injury. 2023 , 281, 109730	O
17	Oral drug delivery platforms for biomedical applications. 2023 , 62, 296-326	О
16	Lactococcus lactis as an Interleukin Delivery System for Prophylaxis and Treatment of Inflammatory and Autoimmune Diseases.	O
15	Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain.	0
14	Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and Mendelian randomisation study.	O
13	Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled doseBscalation study. 2023 , 32, 161-170	0
12	IL-6 SIGNALING EXACERBATES HALLMARKS OF CHRONIC TENDON DISEASE BY STIMULATING PROGENITOR PROLIFERATION & mp; MIGRATION TO DAMAGE.	O

11	A natural goldmine of binding proteins and soluble receptors simplified their translation to blockbuster drugs, all in one decade. 14,	O
10	Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production.	O
9	The Role of Neutrophils in Spondyloarthritis: A Journey across the Spectrum of Disease Manifestations. 2023 , 24, 4108	О
8	Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review. 2023 , 10, 434	O
7	Reduced epilepsy development in synapsin 2 knockout mice with autistic behavior following early systemic treatment with interleukin-6 receptor antibody. 2023 , 191, 107114	O
6	The Physiological and Pathophysiological Role of IL-6/STAT3-Mediated Signal Transduction and STAT3 Binding Partners in Therapeutic Applications. 2023 , 46, 364-378	O
5	Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis. 2023 , 12, 2091	0
4	Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing. 2023, 16, 451	O
3	Association between IL-6 polymorphisms and Atopic Dermatitis in Chinese Han children. 11,	0
2	Targeting IL-6 Signaling Pathways for Musculoskeletal Disorders Treatment: Risks and Benefits. 4, 34-43	O
1	Targeting IL-6 trans-signalling: past, present and future prospects.	0